{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4085","pValueComment":"Two-sided significance level = 0.05","statisticalComment":"Welch t-test (unequal variances)","statisticalMethod":"t-test, 2 sided"}],"anticipatedPostingDate":"2026-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.91","upperLimit":"4.66","value":"-0.62"},{"groupId":"OG001","lowerLimit":"-8.05","upperLimit":"1.09","value":"-3.48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"description":"The MDADI Composite score measures overall swallowing related quality of life derived from the emotional, functional, and physical scores, excluding the global item. Possible scores range from 20 to 100, with higher scores indicating better swallowing related quality of life. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\\^2 IV starts one week prior to RT, then 250 mg/m\\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"RT + Cetuximab"},{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"RT + Durvalumab"}],"paramType":"MEAN","populationDescription":"Randomized participants with baseline and one-year data.","reportingStatus":"POSTED","timeFrame":"Baseline and one year after end of radiation therapy (approximately 7 weeks)","title":"Change in MD Anderson Dysphagia Inventory (MDADI) Composite Score at One Year","type":"SECONDARY","unitOfMeasure":"score on a scale"}